Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.

For over a decade, and as recently as August, FDA has fully evaluated the emerging scientific evidence and repeatedly ...
Barchart on MSN

This Billionaire Investor Is ‘Thrilled’ to Own Kenvue Stock Despite Tylenol Turbulence. Should You Buy KVUE Here?

Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during ...
MPR

FDA and Kenvue Say No Autism Link to Tylenol Use During Pregnancy

“For over a decade, and as recently as August, FDA has fully evaluated the emerging scientific evidence and repeatedly concluded that the data do not support a causal association between acetaminophen ...

Tylenol maker urges FDA to reject calls for autism warning label

Kenvue, the maker of Tylenol, is urging U.S. health regulators not to add an autism warning label to it and other ...

Company behind Tylenol pushing back against proposed changes to safety label

Bessent calls $20 billion lifeline to Argentina a ‘mission-critical’ function of Treasury during shutdown ...
PharmExec

Pharmaceutical Executive Daily: Novo Nordisk's Board Shake-Up

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to ...

Drugs found to reduce advanced prostate cancer death rate

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...
Barchart on MSN

Stocks Retreat on Chipmaker Weakness and Renewed China Tensions

The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -0.53%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down ...